Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation

Description

Postoperative rebleeding is a major limitation of surgical evacuation for intracerebral hemorrhage (ICH). While computed tomography (CT) is the standard of care for postoperative hematoma cavity monitoring, CT requires significant physical and financial costs. Studies have demonstrated varying degrees of efficacy when using transcranial ultrasound to measure ICH volume. Recently, synthetic implants for cranioplasty have been shown to be safe and sonolucent. This study aims to evaluate the ability of transcranial ultrasound with sonolucent cranioplasty (TUSC) to detect and quantify bleeding in postoperative ICH patients.

Conditions

Transcranial Ultrasound With Sonolucent Cranioplasty, TUSC

Talk to us

Study Overview

On this page

Study Details

Study overview

Postoperative rebleeding is a major limitation of surgical evacuation for intracerebral hemorrhage (ICH). While computed tomography (CT) is the standard of care for postoperative hematoma cavity monitoring, CT requires significant physical and financial costs. Studies have demonstrated varying degrees of efficacy when using transcranial ultrasound to measure ICH volume. Recently, synthetic implants for cranioplasty have been shown to be safe and sonolucent. This study aims to evaluate the ability of transcranial ultrasound with sonolucent cranioplasty (TUSC) to detect and quantify bleeding in postoperative ICH patients.

Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation

Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation

Condition
Transcranial Ultrasound With Sonolucent Cranioplasty
Intervention / Treatment

-

Contacts and Locations

New York

Mount Sinai Health System, New York, New York, United States, 10029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Presence of spontaneous supratentorial ICH ≥20 mL
  • * Age ≥18 years
  • * National Institute of Health Stroke Scale (NIHSS) score ≥6
  • * GCS score 5-15 at presentation
  • * Undergoing minimally invasive intracerebral hemorrhage evacuation with sonolucent cranioplasty or hemicraniectomy with sonolucent cranioplasty
  • * Secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct
  • * History of osteomyelitis
  • * History of skull neoplasm
  • * History of comminuted skull fractures
  • * Infratentorial hemorrhage
  • * Midbrain extension/involvement
  • * Coagulopathy defined as INR \> 1.4, elevated aPTT, or concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset; known hereditary or acquired hemorrhagic diathesis; coagulation factor deficiency; platelet count \< 100x103cells/mm3, or known platelet dysfunction
  • * Inability to obtain consent from patient or appropriate surrogate (for patients without capacity)
  • * Evidence of active infection indicated by fever ≥ 100.7F and/or open draining wound at the time of enrolment
  • * Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 1 year
  • * Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up appointment schedule
  • * Active drug or alcohol abuse that, in the opinion of the site investigator, would interfere with adherence to study enrolments
  • * Pre-existing DNR/DNI status

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Icahn School of Medicine at Mount Sinai,

Christopher P. Kellner, MD, PRINCIPAL_INVESTIGATOR, Mount Sinai Health System Department of Neurosurgery

Study Record Dates

2024-09